# NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer

> **NCT07677579** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwell Health** · enrollment: 26 (estimated)

## Conditions studied

- Colon Cancer Metastatic

## Interventions

- **DRUG:** Retifanlimab
- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07677579
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2028-08-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677579, "NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07677579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*